On July 14, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, reported a new installment of its CEO Corner series featuring President and Chief Executive Officer Sanjeev Luther discussing the significant unmet need in ovarian cancer, the Company’s differentiated approach with ERNA-101 and Ernexa’s progress toward advancing its lead cell therapy candidate into the clinic in the fourth quarter of 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ovarian cancer remains one of the deadliest cancers affecting women worldwide. While treatment options have improved over time, many patients eventually experience disease recurrence and progression, leaving limited options for women with platinum-resistant ovarian cancer. In the discussion, Mr. Luther explains how the ability of many ovarian tumors to evade immune detection represents one of the greatest scientific challenges in the disease and why ERNA-101 is designed to help overcome this barrier.
"Every ovarian cancer diagnosis impacts far more than a single patient. It affects families, loved ones and futures, which is why we believe there remains an urgent need for new therapeutic approaches," said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. "At Ernexa, we believe ERNA-101 has the potential to address one of the greatest scientific challenges in ovarian cancer by helping transform immunologically ‘cold’ tumors into tumors the immune system can recognize. This CEO Corner provides additional insight into the science behind our approach, the encouraging preclinical data supporting ERNA-101 and the progress we are making as we advance toward our planned first-in-human Phase 1 study in the fourth quarter of this year."
The discussion also highlights ERNA-101, Ernexa’s lead cell therapy candidate, which is designed to deliver a proprietary immune-activating cytokine directly within the tumor microenvironment with the goal of transforming immunologically "cold" tumors into tumors the immune system can recognize. Mr. Luther also discusses the Company’s proprietary off-the-shelf induced mesenchymal stem cell (iMSC) platform, which the Company believes has the potential to improve manufacturing consistency, increase scalability and ultimately make advanced cell therapies more broadly accessible to patients.
The CEO Corner also reviews encouraging preclinical findings demonstrating complete tumor clearance and 100% long-term survival in preclinical ovarian cancer models when ERNA-101 was combined with PD-1 blockade. Mr. Luther also discusses findings demonstrating remodeling of the tumor microenvironment and increased immune cell infiltration, which further support the scientific rationale behind ERNA-101. He concludes by reviewing the Company’s ongoing manufacturing, regulatory and clinical development activities as Ernexa advances toward its planned IND submission expected in Q3 2026 and anticipated first-in-human clinical study anticipated to start in Q4 2026.
The Ernexa CEO Corner is now accessible on the Company’s website and social media channels. Access it here.
(Press release, Ernexa Therapeutics, JUL 14, 2026, View Source [SID1234669222])